Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study to uncover hidden link between blood mutations and immune disorders

NCT ID NCT05969821

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 5,000 adults with immune system problems to see if certain blood cell mutations (called clonal hematopoiesis) are linked to their condition. Researchers will track new cases of immune-related diseases over time. No treatments or drugs are tested—this is purely an observation study to gather information.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Sep 2045

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The research concerns : * patients whose inflammatory disease without or with haemopathy is already known when the cohort is set up, and for whom data will be collected retrospectively and then prospectively * incident cases identified after the cohort was set up.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>=18 years old; * Confirmed dysimmune manifestations: clinical or biological abnormality or systemic disease; * Presence or absence of myeloid or lymphoid blood disease according to World Health Organization (WHO) classification Exclusion Criteria: * Persons benefiting from special protection: adults under guardianship and curatorship; * People hospitalized without their consent and not protected by law; persons deprived of liberty; * Persons not affiliated to the social security system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease autoinflammatory syndrome chronic myelomonocytic leukemia clonal hematopoiesis clonal hematopoiesis of indeterminate potential hematologic disorder immune system disorder Inflammation inflammatory disease juvenile myelomonocytic leukemia leukemia lymphoma lymphoproliferative syndrome monoclonal gammopathy of uncertain significance myelodysplastic syndrome Myelodysplastic Syndromes myelodysplastic/myeloproliferative disease myelodysplastic/myeloproliferative neoplasm Myeloproliferative Disorders myeloproliferative neoplasm VEXAS syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune diseases Autoinflammatory diseases Clonal hematopoiesis of indeterminate potential Hematologic diseases Hematopoiesis clonal Immune system diseases Inflammation Leukemia Leukemia, myelomonocytic, chronic Lymphoma Lymphoproliferative disorders Monoclonal gammopathy of undetermined significance Myelodysplastic syndromes Myelodysplastic-myeloproliferative diseases Myeloproliferative disorders Vexas syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP, Service de médecine interne, Hôpital Saint Antoine

    Paris, 75012, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.